This is a working overview of Insulin-like growth factor 1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Routine purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Liquid chromatography–mass spectrometry | Mass shift reveals modification or truncation |
| Typical purity specification | Greater than 95 percent | Reported as main-peak area percentage |
| Long-term storage | Minus 20 degrees Celsius or colder | Sealed, protected from light |
| Principal degradation routes | Oxidation, deamidation, aggregation | Monitored individually during stability studies |
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
Radon is a naturally occurring radioactive noble gas discovered in 1900 by Friedrich Ernst Dorn (1848-1916) and is considered carcinogenic. Radon is increasingly found in areas with high levels of uranium and thorium in the soil. These are mainly areas with high granitic rock deposits. According to studies by the World Health Organization, the incidence of lung cancer increases significantly at radiation levels of 100-200 Bq per cubic meter of indoor air. The likelihood of developing lung cancer increases by 10% with each additional 100 Bq/m3 of indoor air.
The class of endorphins consists of three endogenous opioid peptides: α-Endorphin, β-endorphin, and γ-endorphin. The endorphins are all synthesized from the precursor protein, proopiomelanocortin (POMC), and all contain a met-enkephalin motif at their N-terminus: Tyr-Gly-Gly-Phe-Met. α-endorphin and γ-endorphin result from proteolytic cleavage of β-endorphin between the Thr(16)-Leu(17) residues and Leu(17)-Phe(18) respectively. α-endorphin has the shortest sequence, and β-endorphin has the longest sequence. α-Endorphin and γ-endorphin are primarily found in the anterior and intermediate pituitary. While β-endorphin is studied for its opioid activity, α-endorphin and γ-endorphin both lack affinity for opiate receptors and thus do not affect the body in the same way that β-endorphin does. Some studies have characterized α-endorphin activity as similar to that of psychostimulants and γ-endorphin activity to that of neuroleptics separately.
Daniel Siebert identified salvinorin A as the active constituent of Salvia divinorum via self-experimentation in 1993 and published these findings in 1994. Jonathan Ott published a paper on use of salvinorin A by various means and its effects in 1995. D. M. Turner published his book Salvinorin: The Psychedelic Essence of Salvia Divinorum, further describing salvinorin A's hallucinogenic effects in humans, in 1996. Salvinorin A was identified as a highly selective and potent κ-opioid receptor (KOR) agonist by Bryan L. Roth and colleagues in 2002. Dennis McKenna has shared that he identified salvinorin A as an extremely high-affinity KOR ligand while working at Shaman Pharmaceuticals in the early 1990s, but did not publish his findings as he could not believe how potent it was and thought that his results were erroneous. Roland Griffiths and colleagues and other researchers characterized the effects of salvinorin A in humans in formal clinical studies in the 2010s. Griffiths and colleagues further showed that salvinorin A's hallucinogenic and other effects in humans were blocked by the KOR antagonist naltrexone in 2016.
=== Parkinson's disease === In its oral and ODT forms, selegiline is used to treat symptoms of Parkinson's disease (PD). It is most often used as an adjunct to medications such as levodopa (L-DOPA), although it has been used off-label as a monotherapy. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy. Selegiline delays the point when levodopa treatment becomes necessary from about 11 months to about 18 months after diagnosis. There is some evidence that selegiline acts as a neuroprotective and reduces the rate of disease progression, though this is disputed. In addition to parkinsonism, selegiline can improve symptoms of depression in people with Parkinson's disease. There is evidence that selegiline may be more effective than rasagiline in the treatment of Parkinson's disease. This may be due to pharmacological differences between the drugs, such as the catecholaminergic activity enhancer (CAE) actions of selegiline which rasagiline lacks.
Sources: en.wikipedia.org
=== Mid-production reboot === On June 25, Bruce Malmuth left the movie, having only directed thirteen days. Production went dark for three days, after which he was replaced by Craig R. Baxley, who had recently directed I Come in Peace for Diamant. Baxley and Stonebridge were quickly sued for $2 million by Barry & Enright Productions, makers of the TV movie Not of This World, which Baxley had abandoned to take over The Brotherhood, but the dispute was resolved a few weeks later. Malmuth called the split a "non hostile, amicable" one, resulting from his push towards a psychological approach, which Baxley described as "almost too dark". An unnamed crew member told the Los Angeles Times of the influence wielded by Bosworth, and particularly Wichard, on set. Wichard himself took responsibility for streamlining the film, telling the paper: "some 17-year-old kid [was] going to say, 'Oh man, Boz, what are you doing?' I had to sell this movie. I had to give them what they expected." In a 2014 interview, however, Bosworth spoke highly of The Brotherhood's original vision, which had a large subplot dedicated to Huff's family, and deemed that the film would have been better for it. He instead blamed Malmuth and Leonetti's technical mistakes, which supposedly made their footage unusable. Others recalled the axed content in a much less favorable light. In his 2011 memoirs, Henriksen described his original dialogue, which largely consisted of Bible quotes, as "ridiculous", and pleaded with Baxley to let him change it as soon as he arrived.
The endoplasmic reticulum does not harbor an ATP-regeneration machinery, and therefore requires ATP import from mitochondria. The imported ATP is vital for the ER to carry out its house keeping cellular functions, such as for protein folding and trafficking. The ER ATP transporter, SLC35B1/AXER, was recently cloned and characterized, and the mitochondria supply ATP to the ER through a Ca2+-antagonized transport into the ER (CaATiER) mechanism. The CaATiER mechanism shows sensitivity to cytosolic Ca2+ ranging from high nM to low μM range, with the Ca2+-sensing element yet to be identified and validated.
Radon is produced by the radioactive decay of radium-226, which is found in uranium ores, phosphate rock, shales, igneous and metamorphic rocks such as granite, gneiss, and schist, and to a lesser degree, in common rocks such as limestone. Every square mile of surface soil, to a depth of 6 inches (2.6 km2 to a depth of 15 cm), contains about 1 gram of radium, which releases radon in small amounts to the atmosphere. It is estimated that 2.4 billion curies (90 EBq) of radon are released from soil annually worldwide. This is equivalent to some 15.3 kilograms (34 lb). Radon concentration can differ widely from place to place. In the open air, it ranges from 1 to 100 Bq/m3, even less (0.1 Bq/m3) above the ocean. In the United States, the average outdoor radon level is estimated to be 15 Bq/m3 (0.4 pCi/L). In caves or ventilated mines, or poorly ventilated houses, its concentration climbs to 20–2,000 Bq/m3. Radon concentration can be much higher in mining contexts. Ventilation regulations instruct to maintain radon concentration in uranium mines under the "working level", with 95th percentile levels ranging up to nearly 3 WL (546 pCi 222Rn per liter of air; 20.2 kBq/m3, measured from 1976 to 1985). The concentration in the air at the (unventilated) Gastein Healing Gallery averages 43 kBq/m3 (1.2 nCi/L) with maximal value of 160 kBq/m3 (4.3 nCi/L). Radon mostly appears with the radium/uranium series (decay chain) (222Rn), and marginally with the thorium series (220Rn).
Sources: en.wikipedia.org
== Hydrocarbons on other worlds == On Saturn's largest moon, Titan, lakes of liquid hydrocarbons comprising methane, ethane, propane and other constituents occur naturally. Data collected by the space probe Cassini–Huygens yield an estimate that the visible lakes and seas of Titan contain about 300 times the volume of Earth's proven oil reserves. Drilled samples from the surface of Mars taken in 2015 by the Curiosity rover's Mars Science Laboratory have found organic molecules of benzene and propane in 3-billion-year-old rock samples in Gale Crater.
Within the last few years several SMIs with a much higher selectivity towards CK1δ than to other CK1 isoforms have been described which are also effective in animal models. Treatment of rats, mice, monkeys and zebrafishes with PF-670462 (4-[3-cyclohexyl-5-(4-fluoro-phenyl)-3H-imidazol-4-yl]-pyrimidin-2-ylamine) results in a phase shift in circadian rhythm. Furthermore, it blocks amphetamine-induced locomotion in rats, prevents the alcohol deprivation effect in rat, and inhibits acute and chronic bleomycin-induced pulmonary fibrosis in mice. PF-670462 also stalls deterioration caused by UVB eye irradiation in a mouse model of ulcerative colitis, and reduces the accumulation of leukemic cells in the peripheral blood and spleen in a mouse model for Chronic lymphocytic leukemia (CLL). PF-5006739, 4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine derivative attenuate the opioid drug-seeking behavior in rodents. Furthermore, it leads to a phase delay of circadian rhythm in nocturnal and diurnal animal models. N-benzothiazolyl-2-phenyl acetamide derivatives developed by Salado and co-workers show protective effects on in vivo hTDP-43 neurotoxicity in Drosophila. Interestingly, inhibitors of Wnt production (IWPs), known to inhibit O-acyltransferase porcupine (Porcn) and to be antagonists of the Wnt pathway, show structural similarities to benzimidazole-based CK1 inhibitors, among them Bischof-5 and are therefore highly potent in specifically inhibiting CK1δ.
Everyone agrees on the nature and diagnosis of severe GH deficiency, but what are the edges and variations? How should marked constitutional delay be distinguished from partial GH deficiency? To what extent is "normal shortness" a matter of short children naturally making less growth hormone? Can a child make GH in response to a stimulation test but fail to make enough in "daily life" to grow normally? If a stimulation test is used to define deficiency, what GH cutoff should be used to define normal? It was the ethical questions that were new. Whole meetings were devoted to these questions; pediatric endocrinology had become a specialty with its own bioethics issues. Despite the price, the 1990s became an era of experimentation to see what else growth hormone could help. The medical literature of the decade contains hundreds of reports of small trials of GH use in nearly every type of growth failure and shortness imaginable. In most cases, the growth responses were modest. For conditions with a large enough potential market, more rigorous trials were sponsored by pharmaceutical companies that were making growth hormone to achieve approval to market for those specific indications. Turner syndrome and chronic kidney failure were the first of these "nonGH-deficient causes of shortness" to receive FDA approval for GH treatment, and Prader–Willi syndrome and intrauterine growth retardation followed. Similar expansion of use occurred in Europe. One obvious potential market was adult GH deficiency.
On February 3, 1867, the 14-year-old Prince Mutsuhito succeeded his father, Emperor Kōmei, to the Chrysanthemum Throne as the 122nd emperor. This coincided with pressure on the ruling shogunate to modernize Japan, combining modern advances with traditional values. Mutsuhito was sympathetic to these ideas, leading to a call for the restoration of the governing power to the emperor. On November 9, 1867, then-shōgun Tokugawa Yoshinobu tendered his resignation to the Emperor, and "put his prerogatives at the Emperor’s disposal", formally stepping down ten days later. Imperial restoration occurred the next year on January 3, 1868, with the formation of the new government. The fall of Edo in the summer of 1868 marked the end of the Tokugawa shogunate, and a new era, Meiji, was proclaimed. The first reform was the promulgation of the Five Charter Oath in 1868, a general statement of the aims of the Meiji leaders to boost morale and win financial support for the new Meiji government. Its five provisions consisted of:
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.
Removing water slows hydrolysis and limits the mobility that drives aggregation. A dry powder is also less hospitable to microbial growth. These factors make cold storage of the solid form more forgiving than storage of a reconstituted solution.
Methionine oxidation, asparagine and glutamine deamidation, and non-covalent or covalent aggregation are the main routes reported for peptides of this class. Each is tracked as a separate impurity. Their relative abundance depends on formulation and storage history.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.